Alzheimer’s researchers are working hard to find a cure for this disease. They are exploring a number of new approaches and testing a variety of treatments. Right now, almost 6 million Americans are living with this dementia-causing disease.
At the recent 12th annual Clinical Trials on Alzheimer’s Disease (CTAD) — experts shared some just completed research, including a new use for a drug now used for Parkinson’s disease.
Alzheimer’s Researchers: Controlling Hallucinations
Hallucinations, delusions and paranoia are the most common symptoms of Alzheimer’s disease and dementia. However, the fact is that for the more than 2 million Americans who experience them, there is no federally approved treatment
That could change soon. A drug prescribed for Parkinson’s-related psychosis, called Pimavanserin, may also help people with dementia. These results were presented at the conference. Research on the drug was stopped early, when results showed Pimavanserin can increase the time between psychotic episode relapses.
This findings are is a major breakthrough, according to experts at the Neuroscience Division at the National Institute on Aging (NIA).
Dementia Induced Hallucinations
Dementia-related psychosis is very difficult for both people with dementia and their caregivers. In many cases, hallucinations are the reason why someone is no longer able to live at home.
In many cases, caregivers and families are advised to send their loved one to a hospital Emergency Room. This is a really bad idea. Alzheimer’s patients need structure and familiar environments. Therefore, the last thing you want to do is send them to the ER where is no structure, plus it’s frightening.
Acadia Pharmaceuticals, which makes pimavanserin, plans to discuss the study’s results with the Food and Drug Administration (FDA) in the first half of 2020. If approved for use in people with dementia, tis drug would be the first new medicine made available for people living with Alzheimer’s.